HUMAN ANTIBODIES & HYBRIDOMAS

11-13 November 2020, The Richard Doll Building, University of Oxford, Oxford, UK



FIRST CIRCULAR AND CALL FOR PARTICIPATION FOR HAH 2020

Sponsored by the International Journal Human Antibodies · In association with the Integrative Medical Sciences Association

The HAH 2020 scientific programme will have a broadened scope from previous events with the addition of some new topic areas outlined in the scope section below. As usual the scientific programme will include keynote lectures, contributed oral papers and poster presentations emphasising all key aspects of human antibody technologies, applications and engineering.

SCIENTIFIC ADVISORY PANEL

Programme Chairman: Professor Mark Glassy (UCSD Moores Cancer Center, San Diego, California, USA)

Chris Scott (The Queen's University, Belfast, Northern Ireland, UK) Jim Larrick (Panorama Research Inc., USA) Alois Lang (GeNeuro SA, Geneva, Switzerland) David P. Humphreys (UCB, Slough, UK) Markus Enzelberger (MorphoSys AG, Martinsried, Germany) Eszter Nagy (Arsanis GmbH, Vienna, Austria) Sachdev Sidhu (University of Toronto, Canada) Neil Brewis (F-star, Cambridge, UK) Paul Kerr (Fusion Antibodies, Belfast, Northern Ireland, UK) David Naor (The Hebrew University, Jerusalem, Israel) Lynn MacDonald (Regeneron Pharmaceuticals, Tarrytown, New York, USA) Maria Groves (Medimmune, Cambridge, UK) Hermann Katinger and Dietmar Katinger (Polymun Scientific Immunbiologische Forschung GmbH, Vienna, Austria) Andrew T. Serafini (Kilpatrick Townsend, Seattle, Washington, USA) Rick Buick (Fusion Antibodies, Belfast, Northern Ireland, UK) Mohamed Taheri (Beheshti University of Medical sciences, Tehran, Iran)

CONFERENCE SCOPE

The scope of the HAH 2020 conference falls broadly the following main session categories:

Infectious Diseases · Autoimmunity · Molecular Biology · Emerging Technologies Clinical Applications Therapeutic Antibodies · Cancer · Anti-Infective Antibodies · Intellectual Property & Legal Issues

For this and future meetings the scope is being expanded to include sessions on:

Formulation · Oral Delivery · Combination Therapy · Validity of Animal Models Peptide Drugs · Immunotherapy of Cancer & Autoimmunity

HAH 2020 will also have a special focus on Updates on Antibody-Drug Conjugates.

Invited Keynote Speaker: Paul Parren (Lava Therapeutics, Utrecht, The Netherlands)



Abstract Submissions

The HAH 2020 Scientific Advisory Panel require authors to submit a one page abstract for each paper they wish to be considered for inclusion in the oral and/or poster programs during HAH 2020. The one page abstract should contain sufficient information for the committee to be able to make a valid decision as to the intrinsic merit of the paper and its relevance to the aims of the conference. Authors should indicate on the reply form whether they prefer oral or poster presentation. Proposals are also invited for panel discussions and special workshops – these special sessions may be scheduled during the daytime conference timetable or alternatively can be allocated as either breakfast or evening sessions.

Abstract proposals should be sent for the attention of John Herriot at Meetings Management (HAH 2020 Conference Organisers). Authors should send their abstract(s) by e-mail to: jherriot@meetingsmgmt.u-net.com (please attach abstracts as Word documents).

Closing date for submissions intended for oral presentation: Friday 29th May 2020. Authors will be informed of the status of their contribution(s) in June 2020. Closing date for submissions intended for poster presentation: Friday 24th October 2020.

Publication

Abstracts of all papers to be presented (oral and poster) will be included on a USB device which will be distributed to delegates on registration. Authors will be invited to submit their papers to the **Human Antibodies Journal**. All submissions will be refereed in the normal fashion and will be published subsequent to the conference.

Participation

All non-invited speakers will be expected to register as delegates to HAH 2020. Registration will require speakers to pay a registration fee to attend the conference. Travel and accommodation expenses are the responsibility of each non-invited speaker and no direct compensation is awarded for speakers at HAH 2020. Your submission of an abstract testifies to the fact that you will accept these financial conditions.

CALL FOR PARTICIPATION REPLY FORM

 I wish to be placed on the mailing list to receive further information on HAH 2020 I am interested in presenting a paper/poster (abstract attached) – please indicate preferred presentation method 			
Title of abstract:			
Intended session:			
Title (Prof, Dr, Mr, Mrs, Ms):		First Name:	
Last Name:		Organisation:	
Address:			
Postal/Zip Code:		Country:	
Telephone:		Fax:	
E-mail (Please Type/Print):			
	My organisation is interested in sponsoring HAH 2020 $\hfill \square$	Please send me details of exhibition/delegate wallet service	
REQUEST DETAILS OF FUTURE EVENTS			
	 SKIN VACCINATION SUMMIT 2020 – 17-19 March 2020, Edinburgh, Scotland, UK UNIVERSAL INFLUENZA VACCINES – 29-30 April – 1 May 2020, Oxford, UK VIRUS-LIKE PARTICLE & NANO-PARTICLE VACCINES – 15-17 June, Riga, Latvia 		
	PLEASE RETURN THIS FORM TO:		
JOHN HERRIOT, HAH 2020, MEETINGS MANAGEMENT Danehurst, Nore Lane, Hascombe, Godalming, Surrey GU8 4JT, United Kingdom Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516 E-mail: jherriot@meetingsmgmt.u-net.com Website: www.meetingsmanagement.com/hah_2020			